NASDAQ:PACBPacific Biosciences of California Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacific Biosciences of California Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.75 +0.14 (+2.50 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$5.46Now: $5.75▼$5.7850-Day Range$3.38MA: $3.94▼$5.5252-Week Range$2.20Now: $5.75▼$5.94Volume1.74 million shsAverage Volume2.04 million shsMarket Capitalization$887.85 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingPacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Pacific Biosciences of California has a potential upside of 4.3% from its current price of $5.75.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesPacific Biosciences of California has received 411 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPacific Biosciences of California has received 335 “underperform” votes. (Add your “underperform” vote.)Community SentimentPacific Biosciences of California has received 55.09% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote “Outperform” if you believe PACB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 11.00% of the stock of Pacific Biosciences of California is held by insiders.Percentage Held by Institutions76.41% of the stock of Pacific Biosciences of California is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pacific Biosciences of California are expected to decrease in the coming year, from ($0.40) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 15.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB Previous Symbol CUSIP69404D10 CIK1299130 Webwww.pacb.com Phone650-521-8000Debt Debt-to-Equity Ratio0.96 Current Ratio1.15 Quick Ratio1.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90.89 million Price / Sales9.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book15.97Profitability EPS (Most Recent Fiscal Year)($0.55) Net Income$-84,130,000.00 Net Margins-61.85% Return on Equity-150.00% Return on Assets-41.97%Miscellaneous Employees401 Outstanding Shares154,409,000Market Cap$887.85 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $5.75 +0.14 (+2.50 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions How has Pacific Biosciences of California's stock been impacted by COVID-19? Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PACB stock has increased by 67.2% and is now trading at $5.75. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Pacific Biosciences of California? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacific Biosciences of California. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Pacific Biosciences of California. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Monday, August, 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The biotechnology company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $13.84 million. Pacific Biosciences of California had a negative return on equity of 150.00% and a negative net margin of 61.85%. View Pacific Biosciences of California's earnings history. What price target have analysts set for PACB? 3 Wall Street analysts have issued 12 month price targets for Pacific Biosciences of California's stock. Their forecasts range from $5.00 to $7.00. On average, they expect Pacific Biosciences of California's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 4.3% from the stock's current price. View analysts' price targets for Pacific Biosciences of California. Has Pacific Biosciences of California been receiving favorable news coverage? Headlines about PACB stock have trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pacific Biosciences of California earned a news impact score of 0.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Pacific Biosciences of California. Are investors shorting Pacific Biosciences of California? Pacific Biosciences of California saw a decline in short interest in January. As of January 31st, there was short interest totaling 17,210,000 shares, a decline of 13.5% from the January 15th total of 19,890,000 shares. Based on an average trading volume of 2,110,000 shares, the short-interest ratio is presently 8.2 days. Currently, 12.4% of the shares of the company are sold short. View Pacific Biosciences of California's Short Interest. Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD) and FireEye (FEYE). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the following people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)Mr. James Michael Phillips, Sr. VP of R&D (Age 68)Dr. Stephen Turner, Co-Founder & CTO (Age 51)Dr. Jonas Korlach Ph.D., Chief Scientific Officer What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's stock is owned by a variety of retail and institutional investors. Top institutional investors include Bellevue Group AG (5.42%), Vanguard Group Inc. (5.17%), Water Island Capital LLC (3.50%), Gabelli Funds LLC (1.52%), Oracle Investment Management Inc. (0.86%) and Bank of New York Mellon Corp (0.66%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View institutional ownership trends for Pacific Biosciences of California. Which institutional investors are selling Pacific Biosciences of California stock? PACB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Healthcare of Ontario Pension Plan Trust Fund, Assenagon Asset Management S.A., GABELLI & Co INVESTMENT ADVISERS INC., UBS Group AG, Bank of New York Mellon Corp, Marshall Wace LLP, and Water Island Capital LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes. View insider buying and selling activity for Pacific Biosciences of California. Which institutional investors are buying Pacific Biosciences of California stock? PACB stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, Vanguard Group Inc., Platinum Investment Management Ltd., Heartland Advisors Inc., Alps Advisors Inc., Oracle Investment Management Inc., Mutual of America Capital Management LLC, and Moloney Securities Asset Management LLC. View insider buying and selling activity for Pacific Biosciences of California. How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $5.75. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $887.85 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe. What is Pacific Biosciences of California's official website? The official website for Pacific Biosciences of California is www.pacb.com. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
